Humans Age Faster at 2 Sharp Peaks, Study of The Immune System Shows
You're in for a bumpy ride. Don't miss a story, subscribe here.
The immune system employs various strategies to remember threats it encounters, enabling it to mount stronger defenses in the future. A new study, published in Science Immunology on October 30, 2023, sheds light on how cells preserve one type of immune memory over time. The study focused on epigenetics, the methods that cells utilize to control genes without altering their DNA codes.
Epigenetic changes can involve altering how DNA is packaged within cells, which in turn influences gene activity. Previous research has shown that epigenetic changes can prime immune cells for future threats. This type of immune memory, known as trained immunity, enhances the cells' defenses by enabling them to respond more quickly and effectively to future threats.
The mechanism behind the maintenance of this immune memory was previously unclear. Enzymes within cells are typically responsible for removing epigenetic marks, which could otherwise cause the immune memory to fade quickly. However, the new study reveals that the molecule nicotinamide adenine dinucleotide (NAD+) plays a crucial role in maintaining the primed state of immune cells.
Under normal circumstances, NAD+ is consumed during chemical reactions; however, in the context of immune cell epigenetics, NAD+ binds to an epigenetic eraser enzyme called KDM5a without being consumed. Instead, NAD+ effectively "switches off" KDM5a, preventing it from erasing the epigenetic marks that maintain the immune memory.
This finding could have significant implications for treating diseases such as cancer and Alzheimer's, where the immune system's aging and reduced effectiveness play a crucial role. The study suggests that maintaining optimal levels of NAD+ in immune cells might help counteract these conditions.
Written by urgent.news from Live Science's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.